HSCS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient buyer: the trend is still bearish (downside momentum intact) and there is no proprietary buy signal to override the setup.", "Price is below the pivot (3.211) and under stacked bearish moving averages, suggesting rallies are likely to be sold until momentum stabilizes.", "Positive partnership news is a catalyst, but price action and near-term pattern odds still lean negative over the next day/week."]
["Trend: Bearish (SMA_200 > SMA_20 > SMA_5), confirming a sustained downtrend across long/medium/short timeframes.", "Momentum: MACD histogram is negative (-0.0578) and expanding lower, indicating strengthening bearish momentum.", "RSI(6): 25.251 (oversold/washed-out). This can fuel short bounces, but oversold alone is not a durable buy signal while MACD and MAs remain bearish.", "Key levels: Pivot 3.211 (price 3.02 is below), Support S1 2.855 then S2 2.636; Resistance R1 3.566 then R2 3.785.", "Pattern-based outlook: 60% probability of -1.72% next day and -3.67% next week, with a potential +5.82% next month (suggesting any upside may be delayed rather than immediate).", "Intellectia Proprietary Trading Signals: Intellectia Proprietary Trading Signals; - AI Stock Picker: no signal on given stock today.; - SwingMax: No signal on given stock recently."]
["2026-01-29: Partnership with Cibolo Rural Health Networks to deploy MyoVista Insights\u2122 across 123 independent hospitals (potential adoption/usage growth catalyst).", "Insiders and hedge funds show neutral activity (no notable selling pressure signal from these groups in the provided data)."]
["Strong bearish technical structure (bearish MA stack + negatively expanding MACD) suggests continued selling pressure.", "Recent session weakness: -7.86% regular market move to 3.02, indicating fragile sentiment despite a small post-market uptick.", "Near-term probability skew points to further weakness over the next day/week."]
["Latest quarter: 2026/Q2.", "Revenue: 2,419, up 0.00% YoY (flat growth).", "Net income: -2,350,769 (loss), improved 12.86% YoY (loss narrowing).", "EPS: -0.85, down 62.56% YoY (per-share profitability worsened materially).", "Gross margin: 58.33, up 0.00% YoY (stable).", "Overall: operations show some loss improvement at the net level, but EPS deterioration and flat revenue limit the fundamental support for an immediate buy."]
["No analyst rating or price target change data was provided, so a recent Wall Street trend cannot be confirmed.", "Pros view (inferred from available info): partnership announcement supports a growth narrative if it converts into recurring usage/revenue.", "Cons view (inferred from available info): flat revenue and materially worse EPS alongside a bearish chart setup reduce the near-term attractiveness."]
